Hydrocortisone Global Market Report 2024

Hydrocortisone is a corticosteroid hormone naturally produced by the adrenal glands, essential for regulating metabolism and immune responses. It is synthesized and utilized in treating various conditions, primarily serving as an anti-inflammatory agent, commonly applied topically to alleviate skin inflammation and itching.

The principal forms of hydrocortisone include creams, injections, and tablets. Hydrocortisone cream is a topical medication applied directly to the skin to reduce inflammation, itching, and irritation caused by conditions such as eczema, dermatitis, and insect bites. These products are administered via different routes including parenteral, oral, and topical methods, addressing conditions such as adrenocortical dysfunction, adrenergic syndrome, hypercalcemia, thyroiditis, rheumatoid arthritis, dermatitis, asthma, chronic obstructive pulmonary disease (COPD), among others. Distribution channels for hydrocortisone products encompass hospital pharmacies, retail pharmacies, and online platforms.

The hydrocortisone market research report is one of a series of new reports that provides hydrocortisone market statistics, including hydrocortisone industry global market size, regional shares, competitors with an hydrocortisone market share, detailed hydrocortisone market segments, market trends and opportunities, and any further data you may need to thrive in the hydrocortisone industry. This hydrocortisone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hydrocortisone market size has grown strongly in recent years It will grow from $1.43 billion in 2023 to $1.52 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth observed in the historic period can be attributed to several factors, including the increasing prevalence of skin disorders, an aging population, heightened awareness and improved accessibility to treatments, growth within the pharmaceutical industry, and expansion into emerging markets.

The hydrocortisone market size is expected to see strong growth in the next few years It will grow to $1.96 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth in the forecast period can be attributed to advancements in technology, a surge in demand for over-the-counter (OTC) products, increased investments in research and development, rising disposable incomes, and expanded distribution channels. Key trends expected in the forecast period include a focus on natural ingredients, the development of combination therapies, personalized treatment options, the introduction of hydrocortisone-infused products, and a growing emphasis on sustainability.

The hydrocortisone market is expected to grow due to the increasing prevalence of inflammatory and autoimmune diseases. These conditions involve the immune system attacking the body's tissues, leading to chronic inflammation and tissue damage. The rising adoption of treatments for these diseases is driven by their growing prevalence and advancements in medical therapies. Hydrocortisone is utilized in severe asthma exacerbations and other inflammatory and autoimmune diseases to reduce inflammation and improve respiratory function quickly, often administered intravenously in emergency situations. For example, in May 2024, data from the National Center for Health Statistics indicated a rise in asthma prevalence among adults in the United States from 8.4% in 2021 to 8.7% in 2022, with an increase in asthma episodes from 3.3% to 3.7% over the same period.

Leading companies in the hydrocortisone market are focusing on developing combination therapies, such as lotions containing butyrate active ingredients, to enhance treatment effectiveness and expand their product offerings. Hydrocortisone combined with butyrate lotion aims to synergize anti-inflammatory properties with butyrate's immunomodulatory effects, potentially improving skin barrier function in managing skin conditions. For instance, in November 2023, J. Molner AS., an Estonian pharmaceutical firm, launched Hydrocortisone Butyrate Lotion, 0.1%, in the United States, marking a significant step in its strategy to expand globally. This product addresses inflammatory skin conditions, underscoring Molner's commitment to broadening its international market presence.

In March 2022, Advent International Corporation, a US-based private equity firm, acquired Perrigo Company plc's pharmaceutical businesses in Mexico and Brazil, aiming to bolster its regional investment strategy in the pharmaceutical sector. This acquisition strengthens Advent's position in the market, leveraging its extensive industry experience spanning more than two decades. Perrigo Company plc, based in Ireland, specializes in over-the-counter health and wellness solutions, including hydrocortisone creams.

Major companies operating in the hydrocortisone market are Pfizer Inc., Johnson & Johnson, Merck & Co Inc, AbbVie Inc., Bayer AG, Novartis AG, The Dow Chemical Company, GlaxoSmithKline plc (GSK), Viatris Inc., Solvay SA, Teva Pharmaceutical Industries Ltd., Alcon Inc, Sandoz International GmbH, Valeant Pharmaceuticals International Inc, Fresenius Kabi AG, Macleods Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Bausch & Lomb Incorporated, Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Ivax Pharmaceuticals Inc, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Limited, Impax Laboratories LLC, Akorn Incorporated, Taro Pharmaceutical Industries Ltd, Lannett Company Inc, Salix Pharmaceuticals Inc.

North America was the largest region in the hydrocortisone market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hydrocortisone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hydrocortisone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hydrocortisone market consists of sales of hydrocortisone creams, ointments, lotions, and oral formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.